ArticlePloS one2013
Targeted deletion of fibrinogen like protein 1 reveals a novel role in energy substrate utilization.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 85 citations in OpenAlex.
- Hepatokines modulation in obesity: which exercise training model is better in men with obesity?Frontiers in endocrinology · 2025Trial
- Hepassocin prevents age-related liver senescence and facilitates liver regeneration by activating AMPK.Signal transduction and targeted therapy · 2026Article
- The liver-secreted protein FGL1 restrains a subset of innate-like B cell responses via the receptor TACI.Immunity · 2026Article
- Association of Fibrinogen-Like Protein 1 with Metabolic Disorders and Pregnancy Outcomes: A Case-Control StudyEndocrine, metabolic & immune disorders drug targets · 2026Article
- Unraveling fibrinogen-like protein 1's role in immune regulation.Frontiers in immunology · 2026Review
- Regulatory Role of FGL-1 in Interorgan Communication by Controlling T Cell Homeostasis During the Onset of Sjögren Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Ablation of Hepatocyte Derived-FGL1 Does Not Aggravate Metabolic Dysfunction-Associated Steatotic Liver Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Targeting the Opioid System in Cardiovascular Disease: Liver Proteomic and Lipid Profile Effects of Naloxone in Atherosclerosis.Biomedicines · 2025Article
- Therapeutic potential of targeting LAG-3 in cancer.Journal for immunotherapy of cancer · 2025Review
- Yap methylation-induced FGL1 expression suppresses anti-tumor immunity and promotes tumor progression in KRAS-driven lung adenocarcinoma.Cancer communications (London, England) · 2024Article
- Hepatokines: unveiling the molecular and cellular mechanisms connecting hepatic tissue to insulin resistance and inflammation.Acta diabetologica · 2024Review
- Review
- FGL1 and FGL2: emerging regulators of liver health and disease.Biomarker research · 2024Review
- Potential clinical value of fibrinogen-like protein 1 as a serum biomarker for the identification of diabetic cardiomyopathy.Scientific reports · 2024Article
- The interplay between the muscle and liver in the regulation of glucolipid metabolism.Journal of molecular cell biology · 2024Article
- Article
- Article
- FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response.Clinical and experimental immunology · 2024Article
- Systematic review and bioinformatics analysis of plasma and serum extracellular vesicles proteome in type 2 diabetes.Heliyon · 2024Article
- Hepatokines: the missing link in the development of insulin resistance and hyperandrogenism in PCOS?Hormones (Athens, Greece) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Fibrinogen like protein 1(Fgl1) is a secreted protein with mitogenic activity on primary hepatocytes. Fgl1 is expressed in the liver and its expression is enhanced following acute liver injury. In animals with acute liver failure, administration of recombinant Fgl1 results in decreased mortality supporting the notion that Fgl1 stimulates hepatocyte proliferation and/or protects hepatocytes from injury. However, because Fgl1 is secreted and detected in the plasma, it is possible that the role of Fgl1 extends far beyond its effect on hepatocytes. In this study, we show that Fgl1 is additionally expressed in brown adipose tissue. We find that signals elaborated following liver injury also enhance the expression of Fgl1 in brown adipose tissue suggesting that there is a cross talk between the injured liver and adipose tissues. To identify extra hepatic effects, we generated Fgl1 deficient mice. These mice exhibit a phenotype suggestive of a global metabolic defect: Fgl1 null mice are heavier than wild type mates, have abnormal plasma lipid profiles, fasting hyperglycemia with enhanced gluconeogenesis and exhibit differences in white and brown adipose tissue morphology when compared to wild types. Because Fgl1 shares structural similarity to Angiopoietin like factors 2, 3, 4 and 6 which regulate lipid metabolism and energy utilization, we postulate that Fgl1 is a member of an emerging group of proteins with key roles in metabolism and liver regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.